Clinical Study of Merlin's DiVeRt - Vascular Reconstruction Device and Delivery System

NCT ID: NCT04589585

Last Updated: 2022-04-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-06-10

Study Completion Date

2023-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the proposed investigation is to assess the safety and effectiveness of the Merlin's DiVeRt system for the treatment of intracranial lesions.

Merlin is a manufacturer of Flow- Diverters (FD) for Neurovascular applications. The technology is based on a microporous polymer membrane which is delivered to the site of lesion treatment using a metal stent scaffold. The first device in its FD family is the XCalibur Aneurysm Occlusion Device (AOD) system, which is delivered on a rapid-exchange balloon catheter which goes in a 6-Fr guide-catheter. The AOD is CE-marked and has been involved in the treatment of over 70 clinical lesion/aneurysm cases. The same technology is now being made available in a self-expandable stent platform delivered on a 0.028" microcatheter. Merlin has performed the required in-silico, in-vitro and in-vivo tests to be confident of the device performance and now intends to proceed to the human clinical-trials. DiVeRt (Interventional) is a non CE mark device. The device is under clinical trial phase. The competent authority submission for the study has been completed in Spain, Turkey and Hungary.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will recruit patients with intracranial aneurysm (IA) or a lesion located in the anterior or posterior circulation. The analyses of the data from this safety and feasibility study will be descriptive.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intracranial Aneurysm, Wide Neck Aneurysm, Large Neck Aneurysm, Lesion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DiVeRt treatment

DiVeRt device to be used in the single arm

Group Type EXPERIMENTAL

DiVeRt

Intervention Type DEVICE

DiVeRt - Vascular Reconstruction Device and Delivery System

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DiVeRt

DiVeRt - Vascular Reconstruction Device and Delivery System

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject has provided written informed consent using the IRB/EC-approved consent form and agrees to comply with protocol requirements.
* Age 18-80 years.
* Subject has a target intracranial aneurysm (IA) or a lesion located in the anterior or posterior circulation.
* Subject has a target IA with a wide or large neck aneurysm or a lesion. The aneurysm type includes saccular, fusiform, dissecting or blister shapes.

Exclusion Criteria

* Major surgery in the last 30 days.
* History of irreversible bleeding disorder and/or subject presents with signs of active bleeding.
* NIH Stroke Scale ( NIHSS) greater than or equal to 4
* Any known contraindication to treatment with flow diverters.
* Pregnant women.
* Participating in another clinical trial.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Merlin MD Pte Ltd

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Vall De Hebron

Barcelona, , Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sweta Mrs Singh, Masters

Role: CONTACT

68920020 ext. 135

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Alejandro Dr Tomasello

Role: primary

(+34) 93 489 30 00

David Dr Hernandez

Role: backup

(+34) 93 489 30 00

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VV0146

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

INSPIRE Pipeline™ Shield Post Approval Study
NCT05071963 ACTIVE_NOT_RECRUITING
Laser In Situ Fenestration Study
NCT06411990 RECRUITING NA